Full text
Earnings transcript
Read the complete earnings call transcript.
CBZ
CBIZ, Inc.
$54.5
0.01
(0.02%)
| Exchange: | NYSE |
| Market Cap: | 2.924B |
| Shares Outstanding: | 10M |
Delayed data
About The Company
| Sector: | Industrials | |||||
| Industry: | Specialty Business Services | |||||
| CEO: | Jerome Grisko Jr. | |||||
| Full Time Employees: | 9500 | |||||
| Address: |
| |||||
| Website: | https://www.cbiz.com |
CBIZ, Inc. is a professional services firm that delivers a broad spectrum of financial, insurance, and advisory solutions across the United States and Canada. The company’s operations are organized into three principal divisions: Financial Services, Benefits and Insurance Services, and National Practices. Within its Financial Services segment, CBIZ offers expertise in areas such as accountancy and taxation, financial guidance, asset appraisal, risk assessment, and consulting for government healthcare. The Benefits and Insurance Services division focuses on workforce welfare program consultation, compensation and human resources administration, general property and casualty coverage, and pension planning alongside investment solutions. Lastly, the National Practices segment specializes in comprehensive IT infrastructure and hardware management, coupled with specialized healthcare advisory services. CBIZ primarily caters to small and medium-sized enterprises, private individuals, public sector organizations, and various non-profit ventures. The firm was established in 1987 and maintains its principal offices in Cleveland, Ohio.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 1,591,194 | 1,813,472 | 2,757,991 |
| Gross Profit | 223,204 | 182,469 | 355,393 |
| EBITDA | 222,703 | 140,246 | 366,320 |
| Operating Income | 165,239 | 73,716 | 234,010 |
| Net Income | 120,968 | 41,038 | 115,444 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 2,043,592 | 4,470,883 | 4,409,528 |
| Total Liabilities | 1,251,974 | 2,690,900 | 2,647,461 |
| Total Stockholders Equity | 791,618 | 1,779,983 | 1,762,067 |
| Total Debt | 551,014 | 1,833,067 | 528,856 |
| Cash and Cash Equivalents | 8,090 | 13,826 | 18,290 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 153,507 | 123,692 | 192,485 |
| Capital Expenditure | -23,052 | -12,914 | 0 |
| Free Cash Flow | 130,455 | 110,778 | 192,485 |
| Net Income | 120,968 | 0 | 115,444 |
| Net Change in Cash | -2,997 | 30,022 | 30,920 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 3,136,650.758 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 3,193,648.559 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 3,170,177.734 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 371,061.902 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 377,804.672 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 375,028.102 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 414,300.424 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 424,118.434 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 420,075.501 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 144,408.977 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 147,033.111 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 145,952.533 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 6.640 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 6.710 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 6.550 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 1 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 1 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Revenue Growth: CBZ reported third-quarter revenue of $694 million in 2025, reflecting strong top-line performance as highlighted in the earnings call transcript. This growth aligns with the company’s focus on expanding service capabilities and indicates effective market penetration within the industry.
- Positive Earnings Performance: The earnings call summary notes that CBZ exceeded expectations for key financial metrics in Q3 2025, suggesting operational efficiency and effective cost management, which bolsters investor confidence.
- Strong Operating Cash Flow: Historical cash flow statements indicate consistent net cash provided by operating activities, supporting the company’s ability to fund operations and reinvest in growth initiatives without excessive reliance on external financing.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates CBZ intrinsic value between $30.95 – $62.12 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about CBZ valuation
Is CBIZ, Inc. (CBZ) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for CBIZ, Inc. (CBZ) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is CBZ a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether CBZ trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is CBZ’s P/E ratio?
You can see CBZ’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for CBZ?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is CBZ a good long-term investment?
Whether CBZ fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
CBZ
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
0.02
Trading Metrics:
| Open: | 54.45 | Previous Close: | 54.49 | |
| Day Low: | 54.33 | Day High: | 54.62 | |
| Year Low: | 24.29 | Year High: | 67.24 | |
| Price Avg 50: | 37.16 | Price Avg 200: | 39.35 | |
| Volume: | 0 | Average Volume: | 1.093M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeCBZ full analysis
Welcome to MARKETSNAP’s SWOT analysis for CBIZ! If you’re a long-term investor looking to build wealth and grow your portfolio, you’re in the right place. Today, we’re diving deep into CBIZ, a company that might not be a household name for everyone but is definitely worth a closer look. Let’s break down what makes this business tick, analyze its recent performance, and run through a detailed SWOT to see if it’s a fit for your investment strategy. Stick with me,…
